danazol oral / Generic mfg. - LARVOL DELTA

Disease burden and treatment patterns in patients with previously treated primary immune thrombocytopenia (ITP): A retrospective study using administrative claims data in the United States (ASH 2025) - "Following the initial ITP diagnosis, previously treated patients were identified as those who were currently on ITP treatment and who had received one prior therapy comprising an oral corticosteroid, IVIG, IV anti-D, or platelet transfusion, as well as one or more prior therapies comprising TPO-RA, rituximab, fostamatinib, anti-CD-38 monoclonal antibodies, immunosuppressants, danazol, dapsone, bortezomib, vinca alkaloid, or splenectomy. Conclusions Despite receiving at least one currently available first-line and second-line therapy, in this US-based claims study of patients with primary ITP, a significant proportion continued to experience bleeding events and required rescue therapy. This analysis highlights significant unmet needs for novel therapies for the primary ITP patient population."

Retrospective data • Gynecology • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes. (ASH 2025) - "Of the 16 cases, seven received Fludarabine/Busulphan/Antithymocyte globulin (Flu/Bu/ATG) conditioning (Fludarabine 30mg/m 2 day -9 to day -5, Busulphan 3.2mg/kg on day -4 and day -3 and rabbit ATG 2.5mg/kg on day -2 and day -1), seven underwent Fludarabine/Cyclophosphamide (Flu/Cy) conditioning (Fludarabine 25mg/m 2 day -6 to day -2 and Cyclophosphamide 1g/m 2 on day -3 and day -2), and two received Fludarabine/Melphalan (Flu/Mel) (Fludarabine 25mg/m 2 day -6 to day -2 and Melphalan 100mg/m 2 on day -2)...Therapies included Ruxolitnib, Momelotinib, splenic irradiation, Hydroxycarbamide, Danazol, Interferon, Cyclophosphamide, Anagrelide, Thalidomide, Panobinostat and Navitoclax...Although limited by a small sample size, these findings indicate that the Flu/Bu/ATG conditioning regimen may be associated with improved outcomes, thereby supporting its adoption as the preferred approach for patients undergoing allogeneic stem cell transplantation for myelofibrosis as per BSH..."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Myelofibrosis • Pneumonia • Respiratory Diseases • Transplantation • ASXL1 • CALR • JAK2 • SF3B1 • U2AF1

Revisiting accessible therapies for the management of Myelodysplastic Syndromes: A retrospective analysis of danazole, nandrolone or both. (ASH 2025) - "More than half of the patients treated with androgen therapy achieved HI within a median of two months. These results support the potential role of androgens in select patients and reinforce their utility in resource-limited settings or in patient's ineligible for other disease-modifying therapies.The relatively low incidence of death without hematologic response may illustrate a subgroup of non-responding patients who could still benefit from extended androgen therapy or alternative treatments.The low incidence of disease progression and favorable survival outcomes underscore the potential benefit of androgen therapy in this population.Future prospective studies are needed to define predictive markers of response and to explore the role of combination androgen therapy in MDS."

Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome

A case for CD38 targeted therapy in multi-refractory immune thrombocytopenia (ASH 2025) - "Initial treatment with high-dose dexamethasone and IVIG was ineffective. He subsequently received rituximab, eltrombopag and avatrombopag...During weeks 8–14, he was treated with romiplostim, a second steroid pulse, mycophenolate, cyclophosphamide, and cyclosporine without response...While this study is ongoing, we present this case to highlight that daratumumab can be associated with a rapid platelet recovery in multi-refractory ITP, was safe and well tolerated with fostamatinib and danazol, and produced a durable response after a finite treatment course (12 weekly doses). In conclusion, for patients with prolonged, severe ITP unresponsive to conventional treatments, daratumumab offers a rational, mechanism-based intervention. Our case contributes to growing evidence supporting anti-CD38 immunotherapy in ITP and underscores the need for clinical trials to more broadly evaluate other plasma cell directed therapies for the treatment of ITP."

Clinical • Autoimmune Hemolytic Anemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Immune Thrombocytopenic Purpura • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Thrombocytopenia • Thrombocytopenic Purpura

Clinical features and outcomes of myelofibrosis patients with MPL mutations (ASH 2025) - "Treatment regimensincluded JAK inhibitors, most commonly Ruxolitinib (n=31), Momelotinib (n=4), Fedratinib (n=2), andPacritinib (n=1). Anemia-directed therapies included erythropoietin-stimulating agents (ESA) in 21patients, Danazol (n=9), and Luspatercept (n=2)...A significant subset of patients progressed to accelerated-phase disease or AML (n=11, 15%).Despite this, only one-fifth underwent hematopoietic stem cell transplantation. These results highlightedthe need for improved risk stratification and the development of targeted therapeutic strategies for thisrare and understudied population."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • ASXL1 • CALR • JAK2 • SRSF2 • U2AF1

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials (ASH 2025) - P3 | "The presentpost hoc analyses were conducted using a narrower definition restricting achievement of Hb ≥10 g/dL toweek 24 ± a 2-week window, to further evaluate the OS impact of achieving Hb ≥10 g/dL at week 24 withmomelotinib. SIMPLIFY-1 (NCT01969838; JAK inhibitor–naive patients) and MOMENTUM (NCT04173494; JAKinhibitor–experienced patients) were phase 3, randomized, double-blind trials of momelotinib vsruxolitinib or danazol, respectively. These post hoc analyses confirm and expand on previous evidence that, in patients withmoderate to severe anemia regardless of JAK inhibitor exposure, achieving Hb ≥10 g/dL at week 24 withmomelotinib is associated with longer survival. Early intervention with momelotinib to achieve Hbimprovements may support optimal outcomes, as evidenced by the results in JAK inhibitor–naive andmoderately anemic patients compared with JAK inhibitor–experienced or severely anemic patients.Overall, achieving Hb ≥10 g/dL at week 24 per the..."

Clinical • Retrospective data • Anemia • Hematological Disorders • Myelofibrosis • ACVR1 • JAK1 • JAK2

Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia: An exposure-response and time-to-event analysis (ASH 2025) - P3 | "The current analysis aims to characterize therelationship between momelotinib exposure and Hb improvement, as well as the time needed to achievean improvement of ≥1 g/dL, in the MOMENTUM patient population, in which all patients had Hb <10 g/dLat baseline. MOMENTUM (NCT04173494) was a randomized phase 3 trial of momelotinib vs danazol insymptomatic (Total Symptom Score ≥10) and anemic (Hb <10 g/dL), JAK inhibitor–experienced patientswith MF. In JAK inhibitor–experienced patients with baseline Hb <10 g/dL, higher momelotinibexposure was associated with greater anemia-related benefits, including maintenance of increased Hbfrom baseline and faster time to Hb improvement of ≥1 g/dL. The benefits were more pronounced in thehigher quartiles of AUCss (Q3-Q4), highlighting the fact that initiation and maintenance of the full 200-mgdaily dose of momelotinib in line with prescribing information is necessary to ensure optimal outcomes inthis patient population."

Clinical • Anemia • Hematological Disorders • Myelofibrosis • ACVR1 • DLAT • JAK1 • JAK2

Prognostic significance of PNH clones in aplastic anemia treated with immunosuppression or allogeneic HSCT (ASH 2025) - "104(50.3%) patients received IST and 103 (49.7%) patients underwent HSCT as frontline therapy.In the IST cohort, the treatment included cyclosporine plus ATG (horse or rabbit) ± Eltombopag for 77patients (74%) and 27(26%) received other types of IST (Mycophenolate mofetil, danazol, steroid). AA patients with a PNH clone have improved survival with with IST compared to the AA patients without aPNH clone. Post-HSCT both cohorts have good survival, however patients with a PNH clone had lowerchronic GVHD incidence. Further studies to delineate the effect of PNH clone on GVHD incidence areneeded."

Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Complement-mediated Rare Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database (ASH 2025) - "Most pts were treatment naive (n=1564 [69%]); 659 ( hydroxyurea (HU) prior to RUX.During the baseline period, supportive medication for anemia was received by 277 (12%) pts overall(anemia Dx, n=197 [17%]; transfusion, n=102 [26%]), most commonly erythropoiesis-stimulating agents(n=251 [11%]) or danazol (n=43 [2%])...After RUXdiscontinuation, 25% received another MF treatment; the most common treatments were HU (n=256[11%]), fedratinib (n=186 [8%]), and pacritinib (n=115 [5%]). In this real-world study with long-term follow-up of approximately 4 years, median durationof RUX treatment was 3.1 years... In this real-world study with long-term follow-up of approximately 4 years, median durationof RUX treatment was 3.1 years. On average, pts started RUX early after MF diagnosis (median, 4.5 mo),and approximately one-third remained on RUX treatment at end of study period, regardless of age orbaseline anemia status. Most pts did not require transfusions at baseline."

Claims database • Clinical • HEOR • Medicare • Real-world • Real-world evidence • Reimbursement • US reimbursement • Acute Myelogenous Leukemia • Diabetes • Heart Failure • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Myelodysplastic Syndrome • Myelofibrosis • Nephrology • Peripheral Arterial Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases

Clinico-pathological profile and treatment patterns of immune mediated aplastic anemia in resource constrained settings – an analysis from the aplastic anemia registry of India (ASH 2025) - "About 15% of these patients were on combination therapy – Cyclosporine with Danazol orCyclosporine with Eltrombopag. Majority of patients [>65%] in India present to the hospital with Severe or Very Severeaplastic anemia. Androgens and Cyclosporine continue to remain the mainstay of treatment thoughincreasingly TPO agonists are being used in the relapsed refractory setting. Strategies to improve accessto curative treatment options such as ATG and BMT need to be explored."

Anemia • Aplastic Anemia • Gynecology • Hematological Disorders • Hepatology

Prevalence and demographics of autoimmune hemolytic anemia in the United States (ASH 2025) - "Annual prevalence was stratified by age group, sex,and prescription fill for an AIHA-related treatment (systemic steroids, immunosuppressants[azathioprine, mycophenolate, cyclosporin, cyclophosphamide, danazol, bortezomib, rituximab],splenectomy) in the calendar year. AIHA prevalence in this study was consistent with estimates from European countries andhas been increasing in recent years, providing evidence of consistent disease epidemiology across severalgeographies."

Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology

It's not yet time to abandon ruxolitinib in anemic myelofibrosis: Predictive factors of erythroid response to standard anemia-directed therapies combined with ruxolitinib (ASH 2025) - "However, on-target RUX-associated anemia represents a major therapeutic limitation,negatively affecting quality of life, prognosis, and treatment duration.Novel JAK1/2 inhibitors, such as momelotinib and pacritinib, also target ACVR1 and may ameliorateanemia both in RUX-naïve and -exposed pts. However, there is a number of standard anemia-directedtherapies (ADT), including erythropoietin (EPO), danazol, steroids and immunomodulatory agents (e.g.thalidomide), that have been used for a long time to manage anemia in MF...Proactive anemia management with EPO, initiated early before the establishment of TDA, isassociated with better RUX survival and favorable safety profile. These results support a personalizedapproach integrating early prognostic assessment with optimized anemia management strategies, inorder to maximize treatment benefits."

Biomarker • Anemia • Myelofibrosis • ACVR1 • CALR

A prospecitive, multicenter study of chidamide in adult patients with refractory primary immune thrombocytopenia (ASH 2025) - P1/2 | "Eligible participants (at least 18 years old, had ITP for more than 6months, did not respond or relapsed after previous first-line treatment, and lack of response torituximab, TPO agents, or splenectomy) were randomly assigned in a 1:1 ratio to receive chidamide at adosage of either 2.5 mg or 5 mg twice per week...No additional interventions specific to primary immune thrombocytopenia was permitted,except for a stable dose of corticosteroids, TPO-RAs, or danazol before randomization...Chidamide was well tolerated, with the recommended dosage of 5 mg twice per week yielding higheroverall response rates and longer duration of response than the 2.5mg dosage, offering an effectivetherapeutic option for patients with refractory ITP."

Clinical • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura • FOXP3

Clinical profiling and outcomes of ischemic stroke patients with immune thrombocytopenia: A multicenter real-world study (ASH 2025) - "Incontrast, ITP treatments, including danazol, immunoglobulins, rituximab, splenectomy, and TPO-RAs, hadno significant effect on the incidence of post-ITP cerebral infarction. Currently, the management of AIS inITP patients requires close collaboration between hematologists and vascular neurologists to carefullybalance therapeutic benefits against the risk of hemorrhagic complications."

Clinical • Real-world • Real-world evidence • Cardiovascular • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Diabetes • Hematological Disorders • Hypertension • Immune Thrombocytopenic Purpura • Immunology • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura • Vascular Neurology

Autoimmune Thrombocytopenia Treated by Low-Dose Splenic Irradiation Followed by Splenectomy in a Patient With Systemic Lupus Erythematosus. (PubMed, Clin Case Rep) - "Despite multiple therapies, including prednisolone, cyclophosphamide, cyclosporine A, danazol, rituximab, and high-dose IVIg, thrombocytopenia persisted. LDSI (15 Gy in 15 fractions over 5 weeks) was performed, leading to rapid platelet recovery and enabling safe splenectomy, resulting in long-term remission. LDSI can serve as an effective bridging therapy in refractory ATP associated with SLE, allowing safer splenectomy and sustained remission."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • Thrombocytopenia • Thrombocytopenic Purpura

Cyclic Thrombocytopenia Misdiagnosed as Immune Thrombocytopenia (ITP): Diagnostic and Therapeutic Lessons. (PubMed, Cureus) - "Over decades, she underwent extensive ITP-directed therapies, including corticosteroids, intravenous immunoglobulin (IVIG), rituximab, splenectomy, and thrombopoietin receptor agonists (TPO-RAs) like eltrombopag and avatrombopag...Her treatment was adjusted by increasing the avatrombopag dose, with additional consideration for cyclosporine A (CSA) and danazol if platelet cycling persisted...Regular biweekly platelet monitoring may facilitate earlier diagnosis. Better clinical awareness and clearer diagnostic guidelines are needed to reduce misdiagnosis and prevent unnecessary interventions."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Preventive Effects of Eclipta prostrata and Hordeum vulgare Extract Complex on Precocious Puberty in Danazol- and High-Fat Diet-Induced Rat Models. (PubMed, Int J Mol Sci) - "Furthermore, EHEC attenuated the elevation in hypothalamic GnRH mRNA expression observed in both models, without affecting body weight. These findings suggest that EHEC modulates the hypothalamic-pituitary-gonadal axis and may serve as a potential natural therapeutic agent for the prevention of precocious puberty."

Journal • Preclinical

Overall Survival and Erythroid Response in Patients with Low-Risk Myelodysplastic Neoplasms after First-Line Treatment in a Low-Middle Income Country (ASH 2023) - "First line therapy included ESAs, IST (cyclosporine ± eltrombopag), and androgens (mesterolone, danazol). Additionally, IST group showed a better OS. Results obtained with androgens merit further study and should be interpreted with caution because of the sample size."

Clinical • Acute Myelogenous Leukemia • Anemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Characteristics and Long-Term Efficacy of 25 Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab or Ravulizumab in Taiwan (ASH 2024) - "The median LDH level was 6.9 (range 1.67-14.74) times the upper limit of normal (ULN) at baseline.Before receiving eculizumab or ravulizumab, thirteen patients (52%) had previously received other therapies, including steroids in nine patients (36%), cyclosporine and/or anti-thymocyte globulin (ATG) in five (20%), danazol in five (20%), and crovalimab in one (4%) who had been enrolled in a trial...Except for one patient who achieved remission of PNH and three patients who crossed over to clinical trials of iptacopan or pozelimab/cemdisiran, seven patients discontinued eculizumab...Eculizumab and ravulizumab were well-tolerated, and no cases of meningococcal disease were reported.Conclusion : Our experiences demonstrated the clinical characteristics and long-term efficacy and safety of eculizumab and ravulizumab in Taiwanese PNH patients with high disease burdens. However, a major reason for discontinuing treatment was the need for frequent transfusions, which did not meet..."

Clinical • Anemia • Aplastic Anemia • Complement-mediated Rare Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Meningococcal Infections • Myelodysplastic Syndrome • Oncology • Paroxysmal Nocturnal Hemoglobinuria • Pulmonary Disease • Rare Diseases • Renal Disease

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia (ASH 2024) - "Seventy-seven percent of pts had previously received erythropoietin stimulating agents and 11% danazol...The remaining 128 had a median of 1.2 prior lines (range 1-6), with 91% having received ruxolitinib, 3% fedratinib, 21% hydroxyurea, 8.6% corticosteroids, and 4% thalidomide/lenalidomide...Conclusion : Real-life treatment with MMB confirms its marked effect in improving anemia in MF patients, with high rates of patients achieving TI in both iJAK-exposed and iJAK naïve patients. Additionally, MMB has proven effective in reducing symptoms and controlling splenomegaly in pts previously exposed to ruxolitinib, with an acceptable toxicity profile."

Clinical • Real-world • Real-world evidence • Anemia • Anorexia • Bone Marrow Transplantation • Dermatology • Hematological Disorders • Hypotension • Infectious Disease • Myelofibrosis • Nephrology • Pruritus • Renal Disease • Thrombocytopenia • ACVR1 • ASXL1 • CALR • JAK1 • JAK2 • SRSF2 • U2AF1

MODULE 3: Managing MF for Patients with Anemia (ASH 2024) - "This program is supported by educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation and Karyopharm Therapeutics.Rationale for the activity of momelotinib in patients with MF and anemia; differences between momelotinib and other approved JAK inhibitors Key findings from the Phase III MOMENTUM study of momelotinib versus danazol for symptomatic, anemic patients previously treated with a JAK inhibitor Efficacy and safety of momelotinib compared to ruxolitinib in the subset of patients with JAK inhibitor-naïve disease and anemia in the Phase III SIMPLIFY-1 trial FDA approval of momelotinib for patients with MF and disease-related anemia; current role in disease management Comparative tolerability/toxicity profile of momelotinib versus other approved JAK inhibitors Retrospective analysis of the PERSIST-2 study to evaluate the utility of pacritinib for patients with MF and anemia; role, if any, of pacritinib in this setting"

Clinical • Anemia • Hematological Disorders

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials (ASH 2023) - P3 | "SIMPLIFY-1 included pts with JAK inhibitor–naive MF randomized (1:1) to receive MMB or ruxolitinib (RUX). In MOMENTUM, pts with symptomatic (Myelofibrosis Symptom Assessment Form Total Symptom Score ≥10), anemic (hemoglobin <10 g/dL), JAK inhibitor–experienced MF were randomized (2:1) to receive MMB or danazol (DAN)... These data demonstrate that MMB was associated with better maintenance of RBC transfusion intensity and zero RBC transfusion status vs RUX in pts with MF who were JAK inhibitor naive and showed greater reduction in RBC transfusion burden from baseline vs DAN in pts with MF who were JAK inhibitor experienced. Across both trials, ≥85% of pts treated with MMB maintained or improved transfusion intensity."

Clinical • P3 data • Anemia • Hematological Disorders • Myelofibrosis • ACVR1 • JAK2

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study (ASH 2023) - P3 | "While Janus kinase (JAK) inhibitors such as ruxolitinib (RUX) and fedratinib (FED) may address symptoms and splenomegaly, they do not manage and may exacerbate anemia. Treatments for anemia include erythropoiesis-stimulating agents (ESAs), often in combination with RUX or FED, and androgens such as danazol; however, these have shown limited efficacy... In RUX/BAT-treated pts with MF who required RBC transfusions, continued treatment with RUX/BAT in most pts resulted in poor treatment outcomes compared with MMB. Specifically, treatment with MMB demonstrated an ability to deliver higher SVR, TI, and TSS response rates. The lower SVR35 rate in both arms, similar to the overall ITT population, was likely a result of lack of washout from prior JAK inhibitor treatment."

Clinical • P3 data • Anemia • Hematological Disorders • Myelofibrosis • ACVR1 • JAK1 • JAK2

Exploring the Survival Impact and Kinetics of Haemoglobin Improvement with Momelotinib in Patients with Myelofibrosis and Moderate to Severe Anaemia: Post Hoc Analyses of SIMPLIFY-1 and MOMENTUM (DGHO 2025) - "This post hoc analysis of the SIMPLIFY-1 (S1) and MOMENTUM trials provides insights on the kinetics and OS impact of Hb improvements with momelotinib (MMB). S1 and MOMENTUM were randomised, double-blind, phase 3 trials of MMB vs ruxolitinib in JAK inhibitor (JAKi)-naive pts and MMB vs danazol in JAKi-experienced pts, respectively. BL anaemia severity may influence the likelihood and speed of achieving Hb >10 g/dL with MMB. Pts with BL moderate anaemia seem to be more likely to reach this threshold, and faster, than those with severe anaemia, underscoring that intervention with MMB could lead to better outcomes. Achieving Hb >10 g/dL by wk24 with MMB could benefit OS, highlighting it as a positive prognostic factor."

Clinical • Retrospective data • Anemia • Hematological Disorders • Myelofibrosis

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials (ASH 2023) - P3 | "Momelotinib (MMB) is a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 (ACVR1) inhibitor that has demonstrated spleen, symptom, and anemia benefits, including increases in hemoglobin (Hb) and reduction or elimination of red blood cell (RBC) transfusion requirements in pts with MF...Analyses were performed in the safety populations of S1 (N=430; MMB vs ruxolitinib [RUX], JAK inhibitor [JAKi] naive), S2 (N=156; MMB vs best available therapy [88.5% RUX], JAKi experienced), and MOMENTUM (N=195; MMB vs danazol, JAKi experienced)... These data demonstrate that when accounting for differences in known prognostic factors and effect modifiers as well as changes in RBC transfusion status over time, a consistent and statistically significant relationship was observed between transfusion status and OS across all 3 phase 3 MMB trials. Consistent with inclusion of transfusion status in DIPSS-plus risk assessment, these data validate TI status as a clinically relevant and..."

P3 data • Retrospective data • Anemia • Fatigue • Hematological Disorders • Hematological Malignancies • Leukemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • ACVR1 • JAK2